JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

Search

Quidel Corp

Abierto

27.02 1.05

Resumen

Variación precio

24h

Actual

Mínimo

25.95

Máximo

27.05

Métricas clave

By Trading Economics

Empleados

6,600

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+6.38% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

19M

1.6B

Apertura anterior

25.97

Cierre anterior

27.02

Quidel Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 ene 2026, 23:51 UTC

Ganancias

Correction to Samsung Fourth-Quarter Net Profit Article

28 ene 2026, 23:49 UTC

Acciones populares

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 ene 2026, 23:19 UTC

Ganancias

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 ene 2026, 22:43 UTC

Ganancias

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 ene 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 ene 2026, 23:30 UTC

Charlas de Mercado

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 ene 2026, 23:28 UTC

Ganancias

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 ene 2026, 23:26 UTC

Ganancias

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 ene 2026, 23:21 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 23:18 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:58 UTC

Ganancias

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:48 UTC

Charlas de Mercado

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 ene 2026, 22:45 UTC

Ganancias

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 ene 2026, 22:44 UTC

Ganancias

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 ene 2026, 22:43 UTC

Ganancias

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 ene 2026, 22:41 UTC

Ganancias
Acciones populares

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 ene 2026, 22:41 UTC

Charlas de Mercado

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 ene 2026, 22:41 UTC

Ganancias

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 ene 2026, 22:40 UTC

Ganancias

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 ene 2026, 22:39 UTC

Ganancias

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 ene 2026, 22:38 UTC

Ganancias

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 ene 2026, 22:37 UTC

Ganancias

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 ene 2026, 22:35 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 22:26 UTC

Charlas de Mercado
Ganancias

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Comparación entre iguales

Cambio de precio

Quidel Corp Esperado

Precio Objetivo

By TipRanks

6.38% repunte

Estimación a 12 meses

Media 28.5 USD  6.38%

Máximo 35 USD

Mínimo 22 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Quidel Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

1

Comprar

3

Mantener

1

Vender

Finanzas

$

Acerca de Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat